Specialty Chemicals company Tatva Chintan Pharma Chem announced Q3FY25 results Revenue from Operations: Rs 859 million in Q3FY25 (+2% YoY). Total Income: Rs 859 million in Q3FY25 (+1% YoY). EBITDA (Excl. Other Income): Rs 71 million in Q3FY25 (-36% YoY). EBITDA Margin: 8.2% in Q3FY25 (vs. 13.1% in Q3FY24). Profit Before Tax (PBT): Rs (2) million in Q3FY25 (vs. Rs 52 million in Q3FY24). Profit After Tax (PAT): Rs 1 million in Q3FY25 (-96% YoY). PAT Margin: 0.2% in Q3FY25 (vs. 4.1% in Q3FY24). Chairman & MD Chintan Shah Commented: "We endeavor to grow organically by incorporating innovative ideas in our operations, product development and increasing our market presence across product categories" During Q3FY25, the company reported revenue from operations of Rs 859 million, 2% YoY increase. EBITDA during the quarter was at Rs 71 million, 36% YoY decline. EBIDTA margins were at 8.2% v/s 13.1% in Q3FY24. During 9MFY25, the company reported revenue from operations of Rs 2,749 million, 7% YoY decline. EBITDA during same period was at Rs 256 million, 51% YoY decline. EBIDTA margins were at 9.3% v/s 17.8% in 9MFY25. As we step into this promising new year 2025, we at TATVA CHINTAN are confident to finally reap the rewards of the hard work, persistence, and resilience that have defined our efforts over the past few quarters. Overall, the market situation continues to remain subdued in terms of demand but we are beginning to see a faint sense of improvement in the market. Industry as a whole seems to have begun the path to recovery. While we may not have completely left the challenges of the past behind, there are encouraging signs pointing toward better business prospects over the coming quarters. Raw material prices have shown relative stability, and sea freight rates have moderated. We are pleased to inform that we have successfully started distillation plant in January 2025. This new facility will significantly ease production capacities to manufacture some of our major products Our focus is on development of products for use in semiconductor and electronics industry which will become our growth engine after three years. We have made significant headway in coming close to the ultra-high purity quality requirements. In these turbulent times, the strength that has kept us resilient and afloat has been our unwavering R&D; capabilities. Our vision for the future is deeply embedded in the projects we undertake in R&D;, which boasts a robust pipeline of high-value products with immense business potential. Result PDF